These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
815 related articles for article (PubMed ID: 26080839)
41. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317 [TBL] [Abstract][Full Text] [Related]
42. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
43. Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells. López-Royuela N; Balsas P; Galán-Malo P; Anel A; Marzo I; Naval J Biochim Biophys Acta; 2010 Feb; 1803(2):311-22. PubMed ID: 19914305 [TBL] [Abstract][Full Text] [Related]
44. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway. Tsubaki M; Itoh T; Satou T; Imano M; Komai M; Ogawa N; Mukai J; Nishida S Biochem Pharmacol; 2013 Jan; 85(2):163-72. PubMed ID: 23085435 [TBL] [Abstract][Full Text] [Related]
45. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857 [TBL] [Abstract][Full Text] [Related]
46. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity. Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031 [TBL] [Abstract][Full Text] [Related]
51. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Seitz C; Hugle M; Cristofanon S; Tchoghandjian A; Fulda S Int J Cancer; 2013 Jun; 132(11):2682-93. PubMed ID: 23151917 [TBL] [Abstract][Full Text] [Related]
52. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639 [TBL] [Abstract][Full Text] [Related]
53. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685 [TBL] [Abstract][Full Text] [Related]
54. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769 [TBL] [Abstract][Full Text] [Related]
55. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698 [TBL] [Abstract][Full Text] [Related]
56. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231 [TBL] [Abstract][Full Text] [Related]
57. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547 [TBL] [Abstract][Full Text] [Related]
58. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Gazi M; Moharram SA; Marhäll A; Kazi JU Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681 [TBL] [Abstract][Full Text] [Related]
59. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells. Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207 [TBL] [Abstract][Full Text] [Related]
60. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]